RNS Number : 9611L
GSK PLC
13 November 2024
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 13 November 2024

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

115,518

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

115,518

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

673,024

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

155,786

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

517,238

 

 

Name of applicant:

GSK plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2022

Period of return:

From:

1 May 2024

To:

31 October 2024

Balance of unallotted securities under scheme(s) from previous return:

995,257

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see UKLR 20.6.7G):

19,867

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

975,390

 

 

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRDLLFFZFLBFBF